Nullscript inhibits Cryptosporidium and Toxoplasma growth

Fumi Murakoshi, Hironori Bando, Tatsuki Sugi, Oluyomi Stephen Adeyemi, Motohiro Nonaka, Takaaki Nakaya, Kentaro Kato

    研究成果: Article査読

    7 被引用数 (Scopus)


    Cryptosporidium and Toxoplasma are parasites that have caused problems worldwide. Cryptosporidium causes severe watery diarrhoea and may be fatal in immunocompromised patients and in infants. Nitazoxanide is the only agent currently approved by the FDA, but its efficacy is limited. Toxoplasmosis is also a problem in the immunocompromised, as currently available treatment options have limited efficacy and patient tolerance can be poor. In the present investigation, we screened libraries of epigenetic compounds to identify those that inhibited C. parvum growth. Nullscript was identified as a compound with an inhibitory effect on C. parvum and T. gondii growth, and was less toxic to host cells. Nullscript was also able to significantly decrease oocyst excretion in C. parvum-infected SCID mice.

    ジャーナルInternational Journal for Parasitology: Drugs and Drug Resistance
    出版ステータスPublished - 2020 12月

    ASJC Scopus subject areas

    • 寄生虫科
    • 感染症
    • 薬理学(医学)


    「Nullscript inhibits Cryptosporidium and Toxoplasma growth」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。